These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 28879574)
1. Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. Suetani RJ; Siskind D; Reichhold H; Kisely S Psychopharmacology (Berl); 2017 Oct; 234(20):2989-3008. PubMed ID: 28879574 [TBL] [Abstract][Full Text] [Related]
2. Genetic Determinants of Clozapine-Induced Metabolic Side Effects. Vasudev K; Choi YH; Norman R; Kim RB; Schwarz UI Can J Psychiatry; 2017 Feb; 62(2):138-149. PubMed ID: 27681143 [TBL] [Abstract][Full Text] [Related]
3. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Bai YM; Chen TT; Liou YJ; Hong CJ; Tsai SJ Schizophr Res; 2011 Feb; 125(2-3):179-86. PubMed ID: 21185157 [TBL] [Abstract][Full Text] [Related]
4. Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. Zhang Y; Chen M; Chen J; Wu Z; Yu S; Fang Y; Zhang C Psychopharmacology (Berl); 2014 May; 231(10):2211-8. PubMed ID: 24448899 [TBL] [Abstract][Full Text] [Related]
5. Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis. Zhang C; Zhang Y; Cai J; Chen M; Song L Pharmacogenomics J; 2017 Jan; 17(1):92-97. PubMed ID: 26503818 [TBL] [Abstract][Full Text] [Related]
6. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. Mulder H; Cohen D; Scheffer H; Gispen-de Wied C; Arends J; Wilmink FW; Franke B; Egberts AC J Clin Psychopharmacol; 2009 Feb; 29(1):16-20. PubMed ID: 19142101 [TBL] [Abstract][Full Text] [Related]
7. The Relationships of Obesity-Related Genetic Variants With Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients With Schizophrenia. Chen PY; Lu ML; Huang MC; Kao CF; Kuo PH; Chiu CC; Lin SK; Chen CH J Clin Psychopharmacol; 2015 Oct; 35(5):574-8. PubMed ID: 26263223 [TBL] [Abstract][Full Text] [Related]
8. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. Ma X; Maimaitirexiati T; Zhang R; Gui X; Zhang W; Xu G; Hu G Int J Psychiatry Clin Pract; 2014 Oct; 18(4):229-42. PubMed ID: 25152019 [TBL] [Abstract][Full Text] [Related]
9. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. Gunes A; Melkersson KI; Scordo MG; Dahl ML J Clin Psychopharmacol; 2009 Feb; 29(1):65-8. PubMed ID: 19142110 [TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia. Kang SH; Lee JI; Han HR; Soh M; Hong JP Psychiatr Genet; 2014 Dec; 24(6):249-56. PubMed ID: 25304226 [TBL] [Abstract][Full Text] [Related]
11. Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics. Yang L; Chen J; Li Y; Wang Y; Liang S; Shi Y; Shi S; Xu Y World J Biol Psychiatry; 2016 Sep; 17(6):467-74. PubMed ID: 26982812 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of HTR2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs. Puangpetch A; Unaharassamee W; Jiratjintana N; Koomdee N; Sukasem C J Pharm Pharmacol; 2018 Apr; 70(4):536-542. PubMed ID: 29441581 [TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome. Zimbron J; Khandaker GM; Toschi C; Jones PB; Fernandez-Egea E Eur Neuropsychopharmacol; 2016 Sep; 26(9):1353-1365. PubMed ID: 27496573 [TBL] [Abstract][Full Text] [Related]
14. Metabolic predictors for mortality among patients treated with long-term clozapine - A longitudinal study. Taub S; Hoshen M; Balicer R; Kamhi-Nesher S; Weizman A; Krivoy A Eur Neuropsychopharmacol; 2020 Dec; 41():63-69. PubMed ID: 32981820 [TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy? Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650 [TBL] [Abstract][Full Text] [Related]
16. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. Bai YM; Chen JY; Yang WS; Chi YC; Liou YJ; Lin CC; Wang YC; Lin CY; Su TP; Chou P J Clin Psychiatry; 2007 Dec; 68(12):1834-9. PubMed ID: 18162013 [TBL] [Abstract][Full Text] [Related]
17. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. Scheltema Beduin AA; Swets M; Machielsen M; Korver N; J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156 [TBL] [Abstract][Full Text] [Related]
18. Improvements in body composition, anthropometric measurements and lipid profile following discontinuation of clozapine. Wysokiński A; Sobów T Nord J Psychiatry; 2016; 70(2):156-60. PubMed ID: 26140393 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Rietschel M; Naber D; Oberländer H; Holzbach R; Fimmers R; Eggermann K; Möller HJ; Propping P; Nöthen MM Neuropsychopharmacology; 1996 Nov; 15(5):491-6. PubMed ID: 8914122 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Rietschel M; Naber D; Fimmers R; Möller HJ; Propping P; Nöthen MM Neuroreport; 1997 May; 8(8):1999-2003. PubMed ID: 9223092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]